Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2013 Financial Results Business Wire THE WOODLANDS, Texas -- August 13, 2013 Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna^®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the company will report financial results for the three months ended June 30, 2013, before the opening of trading on Wednesday, August 14^th. The company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 8 A.M. Eastern Time on Wednesday, August 14^th. Conference Call and Webcast Details To listen to the conference call, dial in approximately ten minutes before the scheduled 8 AM time to (253) 237-1170 or toll free at (877) 372-0867. Please reference conference ID #31008302 while dialing into the call. A live webcast of the call can also be accessed via the webcast link on our website (www.opexatherapeutics.com) or by going to the following URL: http://investor.shareholder.com/media/eventdetail.cfm?eventid=133472&CompanyID=OPXA&e=1&mediaKey=52AF10A2390CE08BC8D2847172A3B20C There will be a brief Question & Answer session following management commentary. Shareholders and interested parties are highly encouraged to submit questions in advance by e-mail addressed to email@example.com. About Opexa Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. About Multiple Sclerosis (MS) Multiple Sclerosis is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population. For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com About Tcelna Tcelna is a potential personalized therapy that is under development to be specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath™, Opexa's proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response. Opexa is currently conducting a Phase IIb study of Tcelna. Named “Abili-T,” the trial is a randomized, double-blind, placebo-controlled clinical study in patients who demonstrate evidence of disease progression with or without associated relapses. The trial is expected to enroll 180 patients at approximately 30 leading clinical sites in the U.S. and Canada with each patient receiving two annual courses of Tcelna treatment consisting of five subcutaneous injections per year. The trial’s primary efficacy outcome is the percentage of brain volume change (atrophy) at 24 months. Study investigators will also measure several important secondary outcomes commonly associated with MS, including disease progression as measured by the Expanded Disability Status Scale (EDSS), annualized relapse rate and changes in disability as measured by EDSS and the MS Functional Composite. Contact: Company Karthik Radhakrishnan Opexa Therapeutics, Inc. Chief Financial Officer 281-775-0600 firstname.lastname@example.org or Investor Relations Adam Cutler The Trout Group Adam Cutler 646-378-2936 email@example.com
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2013 Financial Results
Press spacebar to pause and continue. Press esc to stop.